Literature DB >> 34233938

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks.

David S Knopman1, Joel S Perlmutter2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34233938      PMCID： PMC8456360          DOI： 10.1212/WNL.0000000000012452

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   11.800


× No keyword cloud information.
  7 in total

Review 1.  The need to show minimum clinically important differences in Alzheimer's disease trials.

Authors:  Kathy Y Liu; Lon S Schneider; Robert Howard
Journal:  Lancet Psychiatry       Date:  2021-06-01       Impact factor: 27.083

2.  Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Authors:  Michael F Egan; James Kost; Tiffini Voss; Yuki Mukai; Paul S Aisen; Jeffrey L Cummings; Pierre N Tariot; Bruno Vellas; Christopher H van Dyck; Merce Boada; Ying Zhang; Wen Li; Christine Furtek; Erin Mahoney; Lyn Harper Mozley; Yi Mo; Cyrille Sur; David Michelson
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

3.  Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.

Authors:  David S Knopman; David T Jones; Michael D Greicius
Journal:  Alzheimers Dement       Date:  2020-11-01       Impact factor: 21.566

4.  Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.

Authors:  Roos J Jutten; Sietske A M Sikkes; Wiesje M Van der Flier; Philip Scheltens; Pieter Jelle Visser; Betty M Tijms
Journal:  Neurology       Date:  2021-06-01       Impact factor: 11.800

5.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

6.  Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.

Authors:  Jeffrey Cummings; Paul Aisen; Cynthia Lemere; Alireza Atri; Marwan Sabbagh; Stephen Salloway
Journal:  Alzheimers Res Ther       Date:  2021-05-10       Impact factor: 6.982

7.  ENGAGE and EMERGE: Truth and consequences?

Authors:  Lewis H Kuller; Oscar L Lopez
Journal:  Alzheimers Dement       Date:  2021-03-03       Impact factor: 21.566
  7 in total
  10 in total

1.  Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia.

Authors:  Lauren J Hunt; Krista L Harrison; Kenneth E Covinsky
Journal:  J Am Geriatr Soc       Date:  2021-09-16       Impact factor: 5.562

2.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

3.  Expedited regulatory product approval in the time of COVID-19.

Authors:  Gary D Novack
Journal:  Ocul Surf       Date:  2022-05-28       Impact factor: 6.268

4.  Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

Authors:  Eric L Ross; Marc S Weinberg; Steven E Arnold
Journal:  JAMA Neurol       Date:  2022-05-01       Impact factor: 29.907

5.  Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors:  Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal:  Neurology       Date:  2022-02-23       Impact factor: 11.800

Review 6.  Cell models for Down syndrome-Alzheimer's disease research.

Authors:  Yixing Wu; Nicole R West; Anita Bhattacharyya; Frances K Wiseman
Journal:  Neuronal Signal       Date:  2022-04-08

Review 7.  Advances in Recapitulating Alzheimer's Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models.

Authors:  Md Fayad Hasan; Eugenia Trushina
Journal:  Brain Sci       Date:  2022-04-26

8.  Editorial: Experimental and Innovative Approaches to Multi-Target Treatment of Parkinson's and Alzheimer's Diseases.

Authors:  Maria A Tikhonova; Hung-Ming Chang; Sandeep Kumar Singh; Didier Vieau
Journal:  Front Neurosci       Date:  2022-05-16       Impact factor: 5.152

9.  Practical Considerations in the Administration of Aducanumab for the Neurologist.

Authors:  Katherine Coerver; Melissa M Yu; Anelyssa D'Abreu; Marc Wasserman; Kavita V Nair
Journal:  Neurol Clin Pract       Date:  2022-04

10.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Authors:  Eleonora Lacorte; Antonio Ancidoni; Valerio Zaccaria; Giulia Remoli; Leonardo Tariciotti; Guido Bellomo; Francesco Sciancalepore; Massimo Corbo; Flavia L Lombardo; Ilaria Bacigalupo; Marco Canevelli; Paola Piscopo; Nicola Vanacore
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.